GlassScriptPhysician profile
Jobeth Mccoy
NPI 1982083705
$877.32
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $213 · 2023: $222 · 2024: $140 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478 · Education: $70.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.57 |
| Education | $70.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $233.86 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $142.48 | 2022-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $129.59 | 2022-2024 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $108.53 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $76.92 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $50.86 | 2025 | Rayaldee |
| Akebia Therapeutics INC | $22.25 | 2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.12 | 2023 | Jardiance |
| Apellis Pharmaceuticals, INC. | $20.43 | 2025 | |
| Travere Therapeutics, INC. | $19.97 | 2024 | |
| Novo Nordisk INC | $18.61 | 2024 | |
| Glaxosmithkline, LLC. | $18.16 | 2023 | Benlysta |
| Ultragenyx Pharmaceutical INC. | $13.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jobeth Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.